With approval for China’s 2nd CAR-T therapy, Juno, WuXi joint venture goes up against Gilead and Fosun’s Yescarta
September 7, 2021
With approval for China's 2nd CAR-T therapy, Juno, WuXi joint venture goes up against Gilead and Fosun's Yescarta
aliu
Fri, 09/03/2021 – 10:00
Read the source article at Pharma News
2021-09-03 15:00:34